MyoKardia is a clinical-stage biopharmaceutical company. Co.'s initial research has focused on genetic mutations in sarcomeric proteins of the heart muscle. Co.'s primary therapeutic candidate, mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). In addition to mavacamten, Co.'s programs include Danicamtiv, an orally-administered small molecule designed to increase cardiac contractility without impairing diastolic filling in patients with systolic heart failure; and MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation. The MYOK stock yearly return is shown above.
The yearly return on the MYOK stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MYOK annual return calculation with any dividends reinvested as applicable (on ex-dates).
|